DE69508985D1 - Polyester Matrix für eine pharmazeutische Zusammensetzung mit verzögerter Freigabe - Google Patents

Polyester Matrix für eine pharmazeutische Zusammensetzung mit verzögerter Freigabe

Info

Publication number
DE69508985D1
DE69508985D1 DE69508985T DE69508985T DE69508985D1 DE 69508985 D1 DE69508985 D1 DE 69508985D1 DE 69508985 T DE69508985 T DE 69508985T DE 69508985 T DE69508985 T DE 69508985T DE 69508985 D1 DE69508985 D1 DE 69508985D1
Authority
DE
Germany
Prior art keywords
sustained
matrix
pharmaceutical composition
stable
delayed release
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69508985T
Other languages
English (en)
Other versions
DE69508985T2 (de
Inventor
Yasutaka Igari
Akira Saikawa
Kayoko Okamoto
Shigeru Kamei
Masahisa Oka
Atsunori Sano
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Takeda Pharmaceutical Co Ltd
Fujifilm Wako Pure Chemical Corp
Original Assignee
Wako Pure Chemical Industries Ltd
Takeda Chemical Industries Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wako Pure Chemical Industries Ltd, Takeda Chemical Industries Ltd filed Critical Wako Pure Chemical Industries Ltd
Application granted granted Critical
Publication of DE69508985D1 publication Critical patent/DE69508985D1/de
Publication of DE69508985T2 publication Critical patent/DE69508985T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
    • C08G63/00—Macromolecular compounds obtained by reactions forming a carboxylic ester link in the main chain of the macromolecule
    • C08G63/02—Polyesters derived from hydroxycarboxylic acids or from polycarboxylic acids and polyhydroxy compounds
    • C08G63/06—Polyesters derived from hydroxycarboxylic acids or from polycarboxylic acids and polyhydroxy compounds derived from hydroxycarboxylic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
    • A61K9/1647—Polyesters, e.g. poly(lactide-co-glycolide)

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Polymers & Plastics (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
DE69508985T 1994-02-21 1995-02-21 Polyester Matrix für eine pharmazeutische Zusammensetzung mit verzögerter Freigabe Expired - Lifetime DE69508985T2 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2288094 1994-02-21
JP2285894 1994-02-21

Publications (2)

Publication Number Publication Date
DE69508985D1 true DE69508985D1 (de) 1999-05-20
DE69508985T2 DE69508985T2 (de) 1999-08-19

Family

ID=26360141

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69508985T Expired - Lifetime DE69508985T2 (de) 1994-02-21 1995-02-21 Polyester Matrix für eine pharmazeutische Zusammensetzung mit verzögerter Freigabe

Country Status (5)

Country Link
US (2) US5594091A (de)
EP (1) EP0668073B1 (de)
AT (1) ATE178789T1 (de)
CA (1) CA2143044C (de)
DE (1) DE69508985T2 (de)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW333456B (en) * 1992-12-07 1998-06-11 Takeda Pharm Ind Co Ltd A pharmaceutical composition of sustained-release preparation the invention relates to a pharmaceutical composition of sustained-release preparation which comprises a physiologically active peptide.
US6090925A (en) 1993-03-09 2000-07-18 Epic Therapeutics, Inc. Macromolecular microparticles and methods of production and use
WO1996028143A1 (de) * 1995-03-10 1996-09-19 Boehringer Mannheim Gmbh Polypeptid-enthaltende pharmazeutische darreichungsformen in form von mikropartikeln und verfahren zu deren herstellung
ATE212545T1 (de) * 1995-03-28 2002-02-15 Fidia Advanced Biopolymers Srl Nanosphären mit einem biokompatiblen polysaccharid
US5759583A (en) * 1995-08-30 1998-06-02 Syntex (U.S.A.) Inc. Sustained release poly (lactic/glycolic) matrices
DE19545257A1 (de) 1995-11-24 1997-06-19 Schering Ag Verfahren zur Herstellung von morphologisch einheitlichen Mikrokapseln sowie nach diesem Verfahren hergestellte Mikrokapseln
US6126919A (en) 1997-02-07 2000-10-03 3M Innovative Properties Company Biocompatible compounds for pharmaceutical drug delivery systems
US5989463A (en) 1997-09-24 1999-11-23 Alkermes Controlled Therapeutics, Inc. Methods for fabricating polymer-based controlled release devices
US6337091B1 (en) 1997-10-27 2002-01-08 Temple University - Of The Commonwealth System Of Higher Education Matrix for controlled delivery of highly soluble pharmaceutical agents
DE69906254T2 (de) * 1998-01-21 2003-11-13 Takeda Chemical Industries Ltd Verfahren zur gerfriertrocknung von präparaten mit verzörgerter wirkstoffabgabe
US6099859A (en) 1998-03-20 2000-08-08 Andrx Pharmaceuticals, Inc. Controlled release oral tablet having a unitary core
JP4719357B2 (ja) † 1998-07-23 2011-07-06 アレス トレイディング ソシエテ アノニム Ｆｓｈ及びｆｓｈ変異体の製剤、製品及び方法
US20030166525A1 (en) 1998-07-23 2003-09-04 Hoffmann James Arthur FSH Formulation
CN1134479C (zh) * 1998-12-15 2004-01-14 武田药品工业株式会社 制备聚合物的方法
US6465425B1 (en) 2000-02-10 2002-10-15 Alkermes Controlled Therapeutics, Inc. Microencapsulation and sustained release of biologically active acid-stable or free sulfhydryl-containing proteins
US7358330B2 (en) * 2001-03-29 2008-04-15 Biotempt B.V. Immunoregulatory compositions
AU5911101A (en) 2000-04-19 2001-10-30 Genentech Inc Sustained release formulations
US6676966B1 (en) 2000-05-09 2004-01-13 Intellipharmaceutics Corp. Extended release metformin hydrochloride formulations
ES2256276T5 (es) * 2000-08-07 2011-02-22 Wako Pure Chemical Industries, Ltd. Polímero de ácido láctico y procedimiento para su producción.
ES2392705T3 (es) * 2000-10-02 2012-12-13 Usv Ltd. Composiciones farmacéuticas de liberación sostenida que contienen metformina y método para su producción
DE10059020A1 (de) * 2000-11-28 2002-05-29 Gruenenthal Gmbh Parenteral applizierbare Darreichungsformen
DE60130917T2 (de) 2000-12-21 2008-07-17 Alrise Biosystems Gmbh Induziertes phasenübergangsverfahren zur herstellung von hydrophile wirkstoffe enthaltenden mikropartikeln
DE60231862D1 (de) * 2001-02-23 2009-05-20 Genentech Inc Erodierbare polymere zur injektion
WO2003000282A1 (en) * 2001-06-21 2003-01-03 Genentech, Inc. Sustained release formulation
JP2004535431A (ja) 2001-06-22 2004-11-25 サザン バイオシステムズ， インコーポレイテッド ゼロ次長期放出同軸インプラント
TWI332407B (en) 2001-06-29 2010-11-01 Takeda Chemical Industries Ltd Controlled release composition and method of producting the same
AU2003288588A1 (en) * 2002-12-16 2004-07-09 Ranbaxy Laboratories Limited An extended release pharmaceutical composition of phenytoin sodium
WO2004077948A1 (ja) * 2002-12-19 2004-09-16 Nippon Soda Co., Ltd. Oil/Water液中乾燥法による農薬マイクロカプセル製剤及びその製造方法
AR043972A1 (es) 2003-04-02 2005-08-17 Ares Trading Sa Formulaciones farmaceuticas de fsh y lh
EP1638595B1 (de) 2003-06-20 2013-03-20 Ares Trading S.A. Gefriergetrocknete fsh / lh formulierungen
WO2005023906A1 (ja) * 2003-09-08 2005-03-17 Chugai Seiyaku Kabushiki Kaisha ヒアルロン酸修飾物、及びそれを用いた薬物担体
WO2005051456A2 (en) * 2003-11-13 2005-06-09 Alza Corporation Composition and apparatus for transdermal delivery
WO2006043644A1 (ja) * 2004-10-20 2006-04-27 National University Corporation Gunma University 温度応答性デプシペプチドポリマー
EP2441460A1 (de) * 2005-06-30 2012-04-18 Ipsen Pharma GLP-1 Pharmazeutische Zusammensetzungen
EP1917971A1 (de) * 2006-10-27 2008-05-07 Société de Conseils de Recherches et d'Applications Scientifiques ( S.C.R.A.S.) Zusammensetzungen mit verlängerter Wirkstofffreigabe, enthaltend Polymere mit sehr niedrigem Molekulargewicht
BRPI0720582B1 (pt) 2006-12-18 2021-08-24 Takeda Pharmaceutical Company Limited Composição de liberação prolongada, processo para a preparação da mesma, composição farmacêutica, agente profilático ou terapêutico, e, uso de uma substância fisiologicamente ativa
US9205577B2 (en) * 2010-02-05 2015-12-08 Allergan, Inc. Porogen compositions, methods of making and uses
US9138309B2 (en) 2010-02-05 2015-09-22 Allergan, Inc. Porous materials, methods of making and uses
US11202853B2 (en) * 2010-05-11 2021-12-21 Allergan, Inc. Porogen compositions, methods of making and uses
US9956164B2 (en) 2014-04-16 2018-05-01 Veyx-Pharma Gmbh Veterinary pharmaceutical composition and use thereof

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NO139560C (no) * 1972-04-29 1979-04-04 Takeda Chemical Industries Ltd Analogifremgangsmaate til fremstilling av terapeutisk virksomme nonapeptidamid-derivater
CS180644B2 (en) * 1973-09-29 1978-01-31 Takeda Chemical Industries Ltd Process for preparing nonapeptides
JPS5726506B2 (de) * 1974-03-08 1982-06-04
NL7611963A (nl) * 1975-10-29 1977-05-03 Parke Davis & Co Werkwijze voor het bereiden van nieuwe nonapep- tiden.
US4093574A (en) * 1977-02-02 1978-06-06 Eli Lilly And Company Somatostatin analogs and intermediates thereto
US4087390A (en) * 1977-02-02 1978-05-02 Eli Lilly And Company Somatostatin analogs and intermediates thereto
DE2635442A1 (de) * 1976-08-06 1978-02-09 Fichtel & Sachs Ag Mehrgang-uebersetzungsnabe fuer fahrraeder o.dgl.
US4100117A (en) * 1977-04-21 1978-07-11 Eli Lilly And Company Somatostatin analogs and intermediates thereto
US4124577A (en) * 1977-06-13 1978-11-07 Warner-Lambert Nonapeptides and methods for their production
US4253998A (en) * 1979-03-09 1981-03-03 American Home Products Corporation Peptides related to somatostatin
JPS54148722A (en) * 1978-05-12 1979-11-21 Takeda Chem Ind Ltd Nonapeptide and its preparation
US4277394A (en) * 1979-04-23 1981-07-07 Takeda Chemical Industries, Ltd Tetrapeptidehydrazide derivatives
US4317815A (en) * 1979-06-13 1982-03-02 Coy David Howard LH-RH Antagonists
US4253997A (en) * 1979-12-17 1981-03-03 American Home Products Corporation Anti-ovulatory decapeptides
FR2537980B1 (fr) * 1982-12-17 1986-12-19 Sandoz Sa Derives d'acides hydroxycarboxyliques oligomeres, leur preparation et leur utilisation
CH656884A5 (de) * 1983-08-26 1986-07-31 Sandoz Ag Polyolester, deren herstellung und verwendung.
JPS60100516A (ja) * 1983-11-04 1985-06-04 Takeda Chem Ind Ltd 徐放型マイクロカプセルの製造法
CH672133A5 (en) * 1984-08-20 1989-10-31 Sandoz Ag New poly-ol ester] deriv. contg. poly- or co:poly-lactic acid residues - useful as degradable matrix for slow release drug formulations
JPH0781000B2 (ja) * 1986-03-12 1995-08-30 扶桑化学工業株式会社 ヒドロキシポリカルボン酸エステルの重合体または共重合体の製造法
JPH0813874B2 (ja) * 1986-10-08 1996-02-14 和光純薬工業株式会社 新規共重合体
US5110904A (en) * 1989-08-07 1992-05-05 Abbott Laboratories Lhrh analogs
JPH02212436A (ja) * 1989-02-14 1990-08-23 Japan Atom Energy Res Inst 徐放性基剤
US5302694A (en) * 1990-02-21 1994-04-12 Boehringer Ingelheim Gmbh Process for preparing polyesters based on hydroxycarboxylic acids
ZA918168B (en) * 1990-10-16 1993-04-14 Takeda Chemical Industries Ltd Prolonged release preparation and polymers thereof.
JPH04173746A (ja) * 1990-11-07 1992-06-22 Unitika Ltd 徐放性機能を有する薬剤・ポリマー複合体
US5319038A (en) * 1993-02-09 1994-06-07 Johnson & Johnson Orthopaedics, Inc. G35 Process of preparing an absorbable polymer

Also Published As

Publication number Publication date
ATE178789T1 (de) 1999-04-15
EP0668073B1 (de) 1999-04-14
CA2143044A1 (en) 1995-08-22
CA2143044C (en) 2005-04-12
US5594091A (en) 1997-01-14
EP0668073A2 (de) 1995-08-23
DE69508985T2 (de) 1999-08-19
US5665394A (en) 1997-09-09
EP0668073A3 (de) 1996-07-24

Similar Documents

Publication Publication Date Title
DE69508985D1 (de) Polyester Matrix für eine pharmazeutische Zusammensetzung mit verzögerter Freigabe
IE940583L (en) Topical antimicrobial pharmaceutical compositions
RU93047799A (ru) Композиции, содержащие ретиноевые кислоты и токоферол
DE69409969D1 (de) Salze der mehrfach ungesättigten fettsäuren und diese enthaltende pharmazeutischen zusammensetzungen
DE69428040T2 (de) Orale darreichungsform
DE3872382D1 (de) Pharmazeutische zusammensetzungen mit verlaengerter wirkung und verfahren zu ihrer herstellung.
CA2009890A1 (en) Valproic acid
RU97107927A (ru) Композиция на основе водных растворов хитозана, повышающие устойчивость растений к болезням
ATE50255T1 (de) Substituierte 9-fluor-3-methyl-7-oxo-2,3-dihydro7h-pyrido(1,2,3-de>(1,4>benzoxazin-6-carbonsaeur ; substituierte 5-amino-6-fluor-1,4-dihydro-4-oxochinolin-3-carbons|ure; substituierte 5-amino-6fluor-1,4-dihydro-4-oxo-1,8-naphthyridin-3- carbonsaeure; ihre derivate; diese enthaltende pharmazeutische zubereitungen und verfahren
DK585889D0 (da) Farmaceutisk praeparat
DE69419365T2 (de) Arzneizusammensetzung mit verzögerter Wirkstoffabgabe enthaltend eine Gallensäure als Wirkstoff
DE69325236T2 (de) Pharmazeutische Zusammensetzungen enthaltend Urodeoxycholicsäure
RU93043304A (ru) Кормовые или медикаментозные композиции для жвачных животных и способ их получения
RU92016533A (ru) Арилалкильные эфиры 4,5-дигидрокси-9,10-дигидро-9,10-диоксо-2-антраценкарбоновой кислоты, обладающие терапевтической активностью, способ их получения, фармкомпозиция
NO883520L (no) Fremgangsmaate for fremstilling av et injeksjonspreparat.
DK0450123T3 (da) Farmaceutisk præparat til topisk administration indeholdende dichlofenac-natrium
ES2060440T3 (es) Derivados de acidos 1,4-dihidropiridin-dicarboxilicos aril-quinolil substituidos, procedimiento para su fabricacion y su uso en medicamentos.
DE69121058D1 (de) Salze von Glykosaminoglykanen mit Aminosäureester, ihre Herstellung sowie sie enthaltende pharmazeutische Zusammensetzungen
NO971879L (no) Preparat for transdermal administrasjon
RU93052408A (ru) Ациламино-алкилиден-гидрокси-бис-фосфоновые кислоты, способ их получения, фармацевтическая композиция
DE69602208T2 (de) Stabilisierte pharmazeutische zusammensetzungen enthaltend dobutamine
IT1233426B (it) Composizioni farmaceutiche per uso orale ad attivita' sequestrante degli acidi biliari contenenti colestiramina quale principio attivo, e procedimento per prepararle
RU93049320A (ru) Фармацевтические композиции
IT1227050B (it) Estere dell'acido 1,8 diacetossiantrachinon 3 carbossilico con l'alfa mercaptopropionilglicina, procedimento per la sua preparazione e composizioni farmaceutiche che lo contengono come principio attivo.
RU94019970A (ru) Водный раствор спарфлоксацина, способ его получения и соль спарфлоксацина и фармацевтическая композиция

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8327 Change in the person/name/address of the patent owner

Owner name: WAKO PURE CHEMICAL INDUSTRIES, LTD., OSAKA, JP

Owner name: TAKEDA PHARMACEUTICAL CO. LTD., OSAKA, JP